Tandler-Schneider A

No ORCID on file · 5 papers in corpus · active 2015-2024
2024
Survey on ART and IUI: legislation, regulation, funding, and registries in European countries-an update.
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deae163

Study questionHow are ART and IUI regulated, funded, and registered in European countries, and how has the situation changed since 2018?Summary answerOf the 43 countries performing ART and IUI in Europe, and participating in the survey, spe…

2021
Psychosomatically Oriented Diagnostics and Therapy for Fertility Disorders. Guideline of the DGPFG (S2k-Level, AWMF Registry Number 016/003, December 2019).
Geburtshilfe und Frauenheilkunde ·doi:10.1055/a-1341-9664

Aim The purpose of this official guideline published and coordinated by the German Society for Psychosomatic Gynecology and Obstetrics [Deutsche Gesellschaft für Psychosomatische Frauenheilkunde und Geburtshilfe (DGPFG)] is to provide a con…

2018
Possible Reasons for Discontinuation of Therapy: an Analysis of 571 071 Treatment Cycles From the German IVF Registry.
Geburtshilfe und Frauenheilkunde ·doi:10.1055/a-0715-2654

Introduction Numerous couples discontinue fertility treatment before achieving the objective, the birth of a child. The aim of this retrospective data analysis is to identify the reasons for early discontinuation of therapy (drop-out). Mate…

2015
Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice.
Drug, healthcare and patient safety ·doi:10.2147/dhps.s77320

PurposeThis postmarketing surveillance survey was conducted to investigate the utility of the CONsistency in r-FSH Starting dOses for individualized tReatmenT (CONSORT) calculator for individualizing recombinant human follicle-stimulating h…

2015
Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction.
Drug, healthcare and patient safety ·doi:10.2147/dhps.s76693

This prospective, noninterventional, post-marketing surveillance study evaluated doses of recombinant human follicle-stimulating hormone (r-hFSH) using the redesigned follitropin alfa pen in women who were anovulatory or oligomenorrheic and…